Clinicians should be alert to this possibility when evaluating patients presenting with unexplained hypoglycemia who report GLP-1 agonist use, especially if obtained from non-pharmacy sources or online
Waardenburg syndrome, a genetic condition characterized by hearing loss and pigmentation abnormalities of the hair, skin, and eyes
telehealth platforms in 2026, depending on your dose level and whether the pharmacy adds vitamin B12 or other compounds
For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory. Commenting on the topline results, Professor Graham Finlayson, chair in psychobiology at the University of Leeds, said it was striking to see retatrutide reaching the weight loss range historically associated with bariatric surgery and that the headline efficacy results are impressive, particularly the proportion of participants reported to achieve very large weight losses. He added: In principle, that broader pharmacology could produce larger effects on body weight and metabolism, although the full peer-reviewed data will be needed to understand the balance between efficacy, tolerability and discontinuation. While this clinical trial did not examine weight regain after stopping retatrutide, other studies have found that discontinuing weight-loss medications such as semaglutide and liraglutide typically results in near-total weight regain within about 18 months
Estas estrategias de marketing han facilitado la penetracin de la semaglutida en el mercado, consolidando su posicin como un medicamento lder
Additionally, conflicting findings suggest that prolonged Metformin treatment may exacerbate AD pathology in genetically susceptible models, increasing -amyloid accumulation, tau phosphorylation, and synaptic dysfunction 63
